Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients
暂无分享,去创建一个
Mark M. Davis | N. Bhatia | M. Roncarolo | E. Meyer | R. Bacchetta | Laura C. Amaya Hernandez | A. Bertaina | Rajni Agarwal-Hashmi | Liwen Xu | A. Cepika | M. Narula | B. Cieniewicz | X. Ji | David M. Louis | P. Shiraz | Nicholas Harre | Keri M. Tate | M. Uyeda | Benjamin Craig Thomas | Gopin Saini | Pauline P. Chen | Dana Margittai | K. Tate | D. M. Louis | P. Chen | G. Saini | Pauline P. Chen | B. C. Thomas
[1] P. Romero,et al. Metabolic Reprogramming of Terminally Exhausted CD8+ T cells by IL-10 Enhances Anti-Tumor Immunity , 2021, Nature Immunology.
[2] K. Papadopoulos,et al. Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study , 2021, International journal of cancer.
[3] J. Nemunaitis,et al. Brief Report: Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination with Pegilodecakin in Patients with Metastatic Non-Small-Cell Lung Cancer (CYPRESS-1 and CYPRESS-2). , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] R. Lechler,et al. The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology , 2020, Frontiers in Immunology.
[5] Cinque S. Soto,et al. High Frequency of Shared Clonotypes in Human T Cell Receptor Repertoires , 2020, Cell reports.
[6] M. Lenardo,et al. A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.
[7] M. Stahl,et al. Suppressive and Gut Reparative Functions of Human Type 1 T-regulatory Cells. , 2019, Gastroenterology.
[8] E. Wherry,et al. Defining ‘T cell exhaustion’ , 2019, Nature Reviews Immunology.
[9] K. Papadopoulos,et al. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. , 2019, The Lancet. Oncology.
[10] Jianjian Peng,et al. Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis. , 2019, Cancer cell.
[11] Hiromasa Morikawa,et al. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer , 2019, Proceedings of the National Academy of Sciences.
[12] Julia T. Chu,et al. Regulatory Type 1 T Cell Infusion in Mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies , 2019, Biology of Blood and Marrow Transplantation.
[13] S. Sakaguchi,et al. Control of Regulatory T Cells by Co-signal Molecules. , 2019, Advances in experimental medicine and biology.
[14] D. Sansom,et al. Measuring CTLA-4-Dependent Suppressive Function in Regulatory T Cells. , 2019, Methods in molecular biology.
[15] J. Gustafsson,et al. Molecular and functional heterogeneity of IL-10-producing CD4+ T cells , 2018, Nature Communications.
[16] Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency , 2018, Journal of Allergy and Clinical Immunology.
[17] M. Battaglia,et al. The Biology of T Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated Diseases. , 2018, Immunity.
[18] M. Roncarolo,et al. Tregopathies: Monogenic diseases resulting in regulatory T‐cell deficiency , 2018, The Journal of allergy and clinical immunology.
[19] Manish R. Patel,et al. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. , 2018, Cancer cell.
[20] R. Flavell,et al. Intestinal IFN‐&ggr;–producing type 1 regulatory T cells coexpress CCR5 and programmed cell death protein 1 and downregulate IL‐10 in the inflamed guts of patients with inflammatory bowel disease , 2018, The Journal of allergy and clinical immunology.
[21] Aviv Regev,et al. Induction and transcriptional regulation of the co-inhibitory gene module in T cells , 2018, Nature.
[22] M. Ansari,et al. A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants , 2018, Scientific Reports.
[23] M. Comi,et al. Interleukin-10-Producing DC-10 Is a Unique Tool to Promote Tolerance Via Antigen-Specific T Regulatory Type 1 Cells , 2018, Front. Immunol..
[24] M. Miyara,et al. Human FOXP3+ T regulatory cell heterogeneity , 2018, Clinical & translational immunology.
[25] M. Roncarolo,et al. IL-10-Engineered Human CD4+ Tr1 Cells Eliminate Myeloid Leukemia in an HLA Class I-Dependent Mechanism , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[26] S. McColl,et al. Eomesodermin promotes the development of type 1 regulatory T (TR1) cells , 2017, Science Immunology.
[27] K. Samitas,et al. Activin-A co-opts IRF4 and AhR signaling to induce human regulatory T cells that restrain asthmatic responses , 2017, Proceedings of the National Academy of Sciences.
[28] Richard Bonneau,et al. Critical role of IRF1 and BATF in forming chromatin landscape during type 1 regulatory cell differentiation , 2017, Nature Immunology.
[29] T. Anagnostou,et al. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation , 2016, Front. Immunol..
[30] Anurag K Singh,et al. Allogeneic Stem Cell Transplantation: A Historical and Scientific Overview. , 2016, Cancer research.
[31] Ana C Anderson,et al. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.
[32] Scott J. Tebbutt,et al. A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes , 2016, Diabetes.
[33] M. Robinson,et al. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. , 2015, F1000Research.
[34] R. Negrin. Graft-versus-host disease versus graft-versus-leukemia. , 2015, Hematology. American Society of Hematology. Education Program.
[35] C. Clish,et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α , 2015, Nature Medicine.
[36] Mikhail Shugay,et al. MiXCR: software for comprehensive adaptive immunity profiling , 2015, Nature Methods.
[37] Marie-Liesse Asselin-Labat,et al. Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses , 2015, Nucleic acids research.
[38] M. Ford,et al. Braking Bad: Novel Mechanisms of CTLA‐4 Inhibition of T Cell Responses , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[39] M. Roncarolo,et al. Mixed chimerism evolution is associated with T regulatory type 1 (Tr1) cells in a β-thalassemic patient after haploidentical haematopoietic stem cell transplantation , 2014, Chimerism.
[40] B. Hemmer,et al. IL-27 and IL-12 oppose pro-inflammatory IL-23 in CD4+ T cells by inducing Blimp1 , 2014, Nature Communications.
[41] H. Volk,et al. Novel GMP‐Compatible Protocol Employing an Allogeneic B Cell Bank for Clonal Expansion of Allospecific Natural Regulatory T Cells , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[42] M. Roncarolo,et al. Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells , 2013, Front. Immunol..
[43] M. Battaglia,et al. Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. , 2014, Current topics in microbiology and immunology.
[44] Charity W. Law,et al. voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.
[45] S. Maiella,et al. Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease. , 2013, Blood.
[46] Clelia Di Serio,et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells , 2013, Nature Medicine.
[47] T. Tamura,et al. Egr‐2 transcription factor is required for Blimp‐1‐mediated IL‐10 production in IL‐27‐stimulated CD4+ T cells , 2013, European journal of immunology.
[48] M. Roncarolo,et al. Enforced IL-10 expression confers type 1 regulatory T cell (Tr1) phenotype and function to human CD4(+) T cells. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[49] A. Amirzargar,et al. Regulatory T-cell subset analysis and profile of interleukin (IL)-10, IL-17 and interferon-gamma cytokine-producing cells in kidney allograft recipients with donor cells infusion , 2012, Clinical and Experimental Nephrology.
[50] M. Roncarolo,et al. Enforced IL-10 Expression Confers Type 1 Regulatory T Cell (Tr1) Phenotype and Function to Human CD4+ T Cells. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[51] T. Mcclanahan,et al. IL-10 elicits IFNγ-dependent tumor immune surveillance. , 2011, Cancer cell.
[52] E John Wherry,et al. T cell exhaustion , 2011 .
[53] Helga Thorvaldsdóttir,et al. Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..
[54] R. Lechler,et al. Human Regulatory T Cells with Alloantigen Specificity Are More Potent Inhibitors of Alloimmune Skin Graft Damage than Polyclonal Regulatory T Cells , 2011, Science Translational Medicine.
[55] Richard A. Moore,et al. Exhaustive T-cell repertoire sequencing of human peripheral blood samples reveals signatures of antigen selection and a directly measured repertoire size of at least 1 million clonotypes. , 2011, Genome research.
[56] G. Anderson,et al. Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4 , 2011, Science.
[57] J. Serody,et al. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. , 2011, Blood.
[58] C. Paties,et al. Molecular and functional characterization of allogantigen-specific anergic T cells suitable for cell therapy , 2010, Haematologica.
[59] E. Hauben,et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. , 2010, Blood.
[60] M. Atkinson,et al. Antigen-Specific Dependence of Tr1-Cell Therapy in Preclinical Models of Islet Transplant , 2009, Diabetes.
[61] Abigail Wacher,et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. , 2009, Blood.
[62] M. Roncarolo,et al. Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia , 2009, Haematologica.
[63] Xiaojing Ma. Faculty Opinions recommendation of Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. , 2009 .
[64] V. Kuchroo,et al. Cutting Edge: IL-27 Induces the Transcription Factor c-Maf, Cytokine IL-21, and the Costimulatory Receptor ICOS that Coordinately Act Together to Promote Differentiation of IL-10-Producing Tr1 Cells1 , 2009, The Journal of Immunology.
[65] Gordon K. Smyth,et al. Testing significance relative to a fold-change threshold is a TREAT , 2009, Bioinform..
[66] C. Carlson,et al. Comprehensive assessment of T-cell receptor (cid:1) -chain diversity in (cid:2)(cid:1) T cells , 2009 .
[67] R. Lechler,et al. Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. , 2008, The Journal of clinical investigation.
[68] Jo-Anne H. Young. Infectious complications of acute and chronic GVHD. , 2008, Best practice & research. Clinical haematology.
[69] P. Halloran,et al. The Transcriptome of Human Cytotoxic T Cells: Similarities and Disparities Among Allostimulated CD4+ CTL, CD8+ CTL and NK cells , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[70] D. Roelen,et al. The ratio of interferon-γ and interleukin-10 producing donor-specific cells as an in vitro monitoring tool for renal transplant patients , 2006 .
[71] D. Klatzmann,et al. Ex Vivo-Expanded CD4+CD25+ Immunoregulatory T Cells Prevent Graft-versus-Host-Disease by Inhibiting Activation/Differentiation of Pathogenic T Cells1 , 2006, The Journal of Immunology.
[72] H. Einsele,et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time , 2005, Bone Marrow Transplantation.
[73] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[74] D. Klatzmann,et al. Ex Vivo-Expanded CD4 CD25 Immunoregulatory T Cells Prevent Graft-versus-Host-Disease by Inhibiting Activation/ Differentiation of Pathogenic T Cells , 2005 .
[75] K. Hudson. Something old and something new. , 2004, The Hastings Center report.
[76] C. Akdis,et al. Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine Balance between Allergen-specific T Regulatory 1 and T Helper 2 Cells , 2004, The Journal of experimental medicine.
[77] T. Mak,et al. Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.
[78] F. Ruscetti,et al. Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. , 1999, Journal of immunology.
[79] Hervé Groux,et al. A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.
[80] J. D. de Vries,et al. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells , 1996, The Journal of experimental medicine.
[81] P. Norman,et al. Immunobiology: The immune system in health and disease , 1995 .
[82] F. Sallusto,et al. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.
[83] R. de Waal Malefyt,et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells , 1994, The Journal of experimental medicine.